Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LaunchPAD-RA: Phase II study of AZD1163 in moderate to severe active rheumatoid arthritis
CTR20261340Phase 2Active
- Sponsor
- AstraZeneca
- Start
- Dec 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of AZD1163 in rheumatoid arthritis (RA), sponsored by AstraZeneca. Started Dec 2025; status: active.
02
Drugs
AZD1163
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on CTR20261340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261340.